[go: up one dir, main page]

NO20076628L - Controlled release nanoparticulate compositions comprising arylheterocyclic compounds - Google Patents

Controlled release nanoparticulate compositions comprising arylheterocyclic compounds

Info

Publication number
NO20076628L
NO20076628L NO20076628A NO20076628A NO20076628L NO 20076628 L NO20076628 L NO 20076628L NO 20076628 A NO20076628 A NO 20076628A NO 20076628 A NO20076628 A NO 20076628A NO 20076628 L NO20076628 L NO 20076628L
Authority
NO
Norway
Prior art keywords
ziprasidone
controlled release
nanoparticulate compositions
composition
schizophrenia
Prior art date
Application number
NO20076628A
Other languages
Norwegian (no)
Inventor
Gurvinder Singh Rekhi
Gary Liversidge
Scott Jenkins
John Devane
Niall Fanning
Paul Stark
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/372,857 external-priority patent/US20060240105A1/en
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20076628L publication Critical patent/NO20076628L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer en sammensetning som omfatter ziprasidon som er nyttig til behandling eller forhindring av schizofreni og lignende psykiatriske lidelser. I en utforming omfatter sammensetningen nanopartikler som omfatter ziprasidon og minst én overflatestabilisator. Nanopartikkelpartiklene har en effektiv gjennomsnittlig partikkelstørrelse på mindre enn omtrent 200 nm. I en annen utforming omfatter sammensetningen en modifisert frigjøringssammensetning som ved administrering til en pasient leverer ziprasidon på en bimodal, multimodal eller kontinuerlig måte. Oppfinnelsen angår også doseringsformer som inneholder slike sammensetninger og fremgangsmåter til behandling og forhindring av schizofreni og lignende psykiatriske lidelser.The present invention provides a composition comprising ziprasidone useful for the treatment or prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticles comprising ziprasidone and at least one surface stabilizer. The nanoparticle particles have an effective average particle size of less than about 200 nm. In another embodiment, the composition comprises a modified release composition which, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions and methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.

NO20076628A 2005-06-20 2007-12-21 Controlled release nanoparticulate compositions comprising arylheterocyclic compounds NO20076628L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69209605P 2005-06-20 2005-06-20
US11/372,857 US20060240105A1 (en) 1998-11-02 2006-03-10 Multiparticulate modified release composition
PCT/US2006/023695 WO2007027273A1 (en) 2005-06-20 2006-06-19 Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds

Publications (1)

Publication Number Publication Date
NO20076628L true NO20076628L (en) 2008-03-12

Family

ID=37809174

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076628A NO20076628L (en) 2005-06-20 2007-12-21 Controlled release nanoparticulate compositions comprising arylheterocyclic compounds

Country Status (12)

Country Link
EP (1) EP1901722A4 (en)
KR (1) KR20080024206A (en)
CN (1) CN101879140A (en)
AU (1) AU2006285349A1 (en)
BR (1) BRPI0612297A2 (en)
CA (1) CA2613474A1 (en)
EA (1) EA200800092A1 (en)
HK (1) HK1117060A1 (en)
IL (1) IL188093A0 (en)
NO (1) NO20076628L (en)
SG (1) SG162811A1 (en)
WO (1) WO2007027273A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2280711A1 (en) * 2008-03-07 2011-02-09 Pfizer Inc. Methods, dosage forms, and kits for administering ziprasidone without food
DE102008045854A1 (en) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Particles of ziprasidone and a disintegrant containing pharmaceutical composition
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
EP3082852B1 (en) * 2013-12-16 2020-06-17 Massachusetts Institute of Technology Micromolded or 3-d printed pulsatile release vaccine formulations
SG10201808645TA (en) 2013-12-16 2018-11-29 Massachusetts Inst Technology Fortified Micronutrient Salt Formulations
MA41611A (en) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc MILLI-CAPSULE PREPARATIONS CONTAINING FREE POLYINSATURATED FATTY ACIDS
JP7776145B2 (en) 2020-05-13 2025-11-26 マサチューセッツ インスティテュート オブ テクノロジー Compositions of polymeric microdevices and their use in cancer immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
KR100477782B1 (en) * 1999-05-27 2005-03-21 화이자 프로덕츠 인코포레이티드 Ziprasidone suspension
CA2503076A1 (en) * 2002-10-25 2004-05-06 Pfizer Products Inc. Novel injectable depot formulations
CN1874761A (en) * 2003-09-02 2006-12-06 辉瑞产品公司 Sustained release dosage forms of ziprasidone
RU2407529C2 (en) * 2005-04-13 2010-12-27 Пфайзер Продактс Инк. Injectable depot formulations and methods for providing prolonged release of nanoparticle compositions

Also Published As

Publication number Publication date
IL188093A0 (en) 2008-03-20
EP1901722A1 (en) 2008-03-26
CN101879140A (en) 2010-11-10
SG162811A1 (en) 2010-07-29
EA200800092A1 (en) 2008-06-30
WO2007027273A1 (en) 2007-03-08
KR20080024206A (en) 2008-03-17
HK1117060A1 (en) 2009-01-09
CA2613474A1 (en) 2007-03-08
AU2006285349A1 (en) 2007-03-08
EP1901722A4 (en) 2011-06-15
BRPI0612297A2 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
NO20073289L (en) Controlled release nanoparticle compositions comprising cephalosporin
NO20076628L (en) Controlled release nanoparticulate compositions comprising arylheterocyclic compounds
NO20080202L (en) Nanoparticulate clopidogrel and aspirin combination formulations
EA200701442A1 (en) COMPOSITIONS OF KANDESARTANA NANOPARTICLES
SG170047A1 (en) Nanoparticulate posaconazole formulations
NO20076215L (en) Nanoparticulate clopidogrel formulations
WO2007035348A3 (en) Nanoparticulate aripiprazole formulations
WO2008008733A3 (en) Nanoparticulate sorafenib formulations
NO20076588L (en) Compositions comprising Nano-Particle and Controlled Release Platelet aggregation inhibitor
EP2481402A3 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2006110809A3 (en) Nanoparticulate lipase inhibitor formulations
WO2008089310A3 (en) Delta 5 desaturase inhibitors for the treatment of obesity
NO20090379L (en) Nanoparticulate modafinil formulations
EA200702641A1 (en) PREPARATIONS OF MESILATE IMATINIB NANOPARTICLES
WO2007033239A3 (en) Nanoparticulate tadalafil formulations
WO2009108720A3 (en) Antagonists of prostaglandin d2 receptors
NO20073334L (en) Nanoparticulate benzothiophene formulations
WO2007053197A3 (en) Nanoparticulate acetaminophen formulations
EP3326630A3 (en) Methods and compositions for treating pulmonary hypertension
EP4495059A3 (en) Silicon nanoparticles for use in treating kidney diseases
MX2010009866A (en) Nanoparticulate compositions of angiogenesis inhibitors.
MX341329B (en) Nanoparticle system comprising oil and uv filter.
WO2008086452A3 (en) Treatment and prevention of alzheimer's disease
JP2008538751A5 (en)
WO2006135689A3 (en) Nanoparticulate ebastine formulations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application